SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ONL Therapeutics Completes Enrollment in Phase 2 GALAXY Trial

ONL Therapeutics completed enrollment in its global Phase 2 trial of xelafaslatide in patients with geographic atrophy associated with dry age-related macular degeneration.

Related stories